Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Infectious Diseases

• Publication date

  2006-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/508188PMID 17109310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE

  2006cited by this paper
• Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

  2006cited by this paper
• The In Vivo Glucuronidation of Buprenorphine and Norbuprenorphine Determined by Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry

  2006cited by this paper
• Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents.

  2005cited by this paper
• Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

  2004cited by this paper
• Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir.

  2004cited by this paper
• Office‐Based Buprenorphine Treatment for Opioid‐Dependent Patients

  2004cited by this paper
• Reverse Phase High-Performance Liquid Chromatography Method for the Analysis of Amprenavir, Efavirenz, Indinavir, Lopinavir, Nelfinavir and Its Active Metabolite (M8), Ritonavir, and Saquinavir in Heparinized Human Plasma

  2003cited by this paper
• The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

  2003cited by this paper
• Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users

  2002cited by this paper
• HIV-1 infection in injection drug users.

  2002cited by this paper
• Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

  2002cited by this paper
• Modified directly observed therapy (MDOT) for injection drug users with HIV disease.

  2002cited by this paper
• Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.

  2001cited by this paper
• Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV‐1 Infection

  2001cited by this paper
• Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users

  2001cited by this paper
• Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives.

  2001cited by this paper
• Nelfinavir: an update on its use in HIV infection.

  2000cited by this paper
• Hepatitis C: an update on the silent epidemic.

  2000cited by this paper
• Interaction of methadone with didanosine and stavudine.

  2000cited by this paper
• Nelfinavir

  2000cited by this paper
• Treatment for drug dependence.

  1999cited by this paper
• Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.

  1999cited by this paper
• Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.

  1998cited by this paper
• Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.

  1998cited by this paper
• Barriers to use of free antiretroviral therapy in injection drug users.

  1998cited by this paper
• Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262).

  1998cited by this paper
• The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone.

  1997cited by this paper
• Potential factors affecting adherence with HIV therapy

  1997cited by this paper
• Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.

  1996cited by this paper
• The impact of HIV infection on medical services in drug abuse treatment programs.

  1996cited by this paper
• Medical care for injection-drug users with human immunodeficiency virus infection.

  1994cited by this paper
• Two new rating scales for opiate withdrawal.

  1987cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• In this Supplement

  1935cited by this paper

• Considerations when prescribing opioid agonist therapies for people living with HIV

  2024cites this paper
• Safely prescribing opioids with Nirmatrelvir/Ritonavir - Case report and management recommendations.

  2023cites this paper
• A Review of the Safety of Buprenorphine in Special Populations.

  2022cites this paper
• In Reply.

  2022cites this paper
• Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.

  2022cites this paper
• The role of cannabis in pain management among people living with HIV who use drugs: A qualitative study.

  2021cites this paper
• A Narrative Systematic Literature Review: A Focus on Qualitative Studies on HIV and Medication-Assisted Therapy in the United States

  2021cites this paper
• Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route

  2021cites this paper
• [Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].

  2020cites this paper
• Opioid Use Disorders in People Living with HIV/AIDS: A Review of Implications for Patient Outcomes, Drug Interactions, and Neurocognitive Disorders

  2020cites this paper
• Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability

  2019cites this paper
• Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation

  2018cites this paper
• Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs

  2018cites this paper
• Understanding Pregnancy-induced Changes in the Disposition of Norbuprenorphine, Metformin and Glyburide in Mice and Humans for Optimizing Drug Therapy during Pregnancy

  2018cites this paper
• Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction

  2016cites this paper
• [Interaction of opioid analgesics at the level of biotransformation].

  2016cites this paper
• Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects

  2016cites this paper
• Opioid Receptor Agonists and Antagonists

  2016cites this paper
• Interaktionen der Opioidanalgetika auf Ebene der Biotransformation

  2016cites this paper
• Ritonavir Use in Human Immunodeficiency Virus–Positive Surgical Patients Is Not Associated with an Increase in Postoperative Critical Respiratory Events

  2016cites this paper
• Buprenorphine for Cancer Pain

  2015cites this paper
• Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.

  2014cites this paper
• Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information

  2014cites this paper
• A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

  2013cites this paper
• P-glycoprotein (P-gp/MDR1)/ABCB1

  2013cites this paper
• Buprenorphine Pharmacodynamics and Pharmacokinetics

  2013cites this paper
• Psychopharmacological treatments in HIV patients under antiretroviral therapy.

  2012cites this paper
• Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

  2012cites this paper
• Prescription Long-term Opioid Use in HIV-infected Patients

  2012cites this paper
• Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Patients: Does It Serve as a Bridge to Hepatitis C Virus Therapy?

  2012cites this paper
• Buprenorphine/Naloxone

  2012cites this paper
• Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

  2011cites this paper
• Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

  2011cites this paper
• Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone

  2011cites this paper
• Drug interactions of opioid analgesics – strong opioids

  2011cites this paper
• Buprenorphine/Naloxone for opioid dependence: clinical practice guideline.

  2011cites this paper
• Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

  2011cites this paper
• Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients

  2011cites this paper
• Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction

  2011cites this paper
• Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone

  2011cites this paper
• Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

  2010cites this paper
• The Triple Threat: Mental Illness, Substance Abuse, and the Human Immunodeficiency Virus

  2010cites this paper
• Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users

  2010cites this paper
• Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells

  2010cites this paper
• Title Methadone , Buprenorphine , and Street Drug Interactions with Antiretroviral Medications Permalink

  2010cites this paper
• Effect of cocaine use on buprenorphine pharmacokinetics in humans.

  2010cites this paper
• Introduction to Drug Transporters

  2010cites this paper
• Integrated Opioid Use Disorder and HIV Treatment: Rationale, Clinical Guidelines for Addiction Treatment, and Review of Interactions of Antiretroviral Agents and Opioid Agonist Therapies

  2010cites this paper
• Methadone, Buprenorphine, and Street Drug Interactions with Antiretroviral Medications

  2010cites this paper
• Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir

  2010cites this paper
• Interventions for HIV and hepatitis C virus infections in recreational drug users.

  2010cites this paper
• Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective.

  2010cites this paper
• Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

  2010cites this paper
• Effect of Rifampin and Nelfinavir on the Metabolism of Methadone and Buprenorphine in Primary Cultures of Human Hepatocytes

  2009influential citation
• Pharmacology of opioid agonists and antagonists

  2009cites this paper
• Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users.

  2009cites this paper
• The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.

  2009cites this paper
• Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice

  2008cites this paper
• Current health disparities in HIV/AIDS.

  2008cites this paper
• Medical Consequences of Drug Abuse and Co-Occurring Infections

  2008cites this paper
• Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice

  2008cites this paper
• Clinical Manual of Drug Interaction Principles for Medical Practice

  2008cites this paper
• Antiretroviral therapy and anaesthesia

  2008cites this paper
• CHAPTER 44 – HIV Disease Among Substance Users: Treatment Issues

  2008cites this paper
• Dosing Adjustments in Postpartum Patients Maintained on Buprenorphine or Methadone

  2008cites this paper
• Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

  2008cites this paper
• Management of HIV infection in patients with substance use problems

  2008cites this paper
• Drug interactions in the management of HIV infection: an update

  2007cites this paper
• Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

  2007cites this paper
• Endogenous opiates and behavior: 2006.

  2007cites this paper
• Medical Consequences of Drug Abuse and Co-occurring Infections: A Brief Review

  2007cites this paper
• Illicit drugs, alcohol, and addiction in human immunodeficiency virus.

  2007cites this paper
• Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

  2007cites this paper
• Pharmacokinetic interactions between buprenorphine and antiretroviral medications.

  2006cites this paper
• Buprenorphine and HIV primary care: new opportunities for integrated treatment.

  2006cites this paper
• Guideline for Physicians Working in California Opioid Treatment Programs

  2005cites this paper